SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 11.2% – Here’s What HappenedDefense World · Oct 18, 2026
SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier StudyGuruFocus · Oct 15, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSGlobeNewsWire · Oct 6, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSPRNewsWire · Oct 1, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSGlobeNewsWire · Sep 29, 2026
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic CancerGlobeNewsWire · Sep 25, 2026SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.05 | -$0.05 | Miss |
| May 12, 2026 | -$0.06 | -$0.05 | Beat |
| Mar 19, 2026 | -$0.06 | -$0.05 | Beat |
| Nov 12, 2025 | -$0.06 | -$0.06 | Beat |
| Aug 12, 2025 | -$0.08 | -$0.07 | Beat |
| May 13, 2025 | -$0.10 | -$0.07 | Beat |